• Explore /
  • Poster
  • / Safety and clinical activity of MEDI4736, an anti-programmed cell death-ligand 1 (PD-L1) antibody, in patients with non-small cell lung cancer (NSCLC).

Safety and clinical activity of MEDI4736, an anti-programmed cell death-ligand 1 (PD-L1) antibody, in patients with non-small cell lung cancer (NSCLC).

Abstract Poster

Authors

null

Naiyer A. Rizvi

Columbia University Medical Center, New York, NY

Naiyer A. Rizvi , Julie R. Brahmer , Sai-Hong Ignatius Ou , Neil Howard Segal , Samir Khleif , Wen-Jen Hwu , Martin Gutierrez , Patrick Schoffski , Omid Hamid , Jared Weiss , Jose Lutzky , Michele Maio , John J. Nemunaitis , Dirk Jaeger , Ani Sarkis Balmanoukian , Marlon Rebelatto , Keith Steele , Xia Li , John A. Blake-Haskins , Scott Joseph Antonia

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2015 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Lung Cancer—Non-Small Cell Metastatic

Track

Lung Cancer

Sub Track

Metastatic Non–Small Cell Lung Cancer

Clinical Trial Registration Number

NCT01693562

Citation

J Clin Oncol 33, 2015 (suppl; abstr 8032)

DOI

10.1200/jco.2015.33.15_suppl.8032

Abstract #

8032

Poster Bd #

354

Abstract Disclosures

Similar Posters

First Author: Haruo Iguchi

First Author: Neil Howard Segal

First Author: Guillermo Garcia-Manero

First Author: Panpan Zhang